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       INTRODUCTION 
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Obesity is a medical condition in which excess body fat gets accumulated 
to  an  extent  that  it  may  have an adverse effect on health, leading to 
reduced life expectancy and  increased health problems. 
 The need for weight and fitness guideline, specific to Asian 
countries was stressed in a study by the world health organization’s sub- 
committee setup, to look into obesity and metabolic syndrome in the Asia 
-Pacific region in 2000. Health ministry of India, in association with 
Diabetes foundation of India, All India institute of medical science, 
Indian Council of Medical research, National Institute of Nutrition and 
other 20 health organizations released a joint revised guidelines for 
obesity in India. 
 The guidelines estimate that the absolute mortality due to chronic 
heart diseases in India is 1.59 million annually in the year 2000, which 
may reach 2.58 million around 2020. 
  The current load of diabetes in the country is 41 million and is 
expected to rise by 170% in the next 20 years In 2050 India may become 
the global capital diabetes mellitus. 
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For every extra 10 kilogram, above the stipulated body weight [measured 
according to height], life expectancy a person reduces by three years. 
Obesity  can  be  considered  as  the  gateway for the  development  of  
metabolic  syndrome  in  the   affected  individuals. In  this  modern  
world  sedentary  life  style and  diet  habits  in  combination  with  stress  
increases  the  chances  of  acquiring  obesity. 
                                  Insulin  resistance,  dyslipidemia   and  hypertension  
are  the  three  major  disease   conditions  related  obesity  and  are  being  
the  factors  which  increases  the morbidity  and  mortality  in  obese  
individuals. 
                                 In obesity excess visceral adipose tissue plays an 
important role in altering the homeostasis between the pro inflammatory 
and anti inflammatory cytokines which leads to series of biochemical 
reactions in body and thereby producing many disease states. 
                                 These reactions are mediated by various 
inflammatory cytokines that leads to the development of insulin 
resistance, alteration in the lipid profile and cardiovascular diseases. 
Among them, some of the important cytokines that are involved in the 
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pathogenesis of obesity related diseases are adiponectins, leptins, TNF-α, 
Interleukin-6 and reistins. 
 
Interleukin -6 is an important cytokine which has pro inflammatory    
and anti inflammatory activity. In obesity the IL-6 that are secreted by the 
macrophages in the excess visceral adipose tissue predominantly act’s as 
a pro inflammatory cytokine. 
             Increased levels of IL-6 and its pro- inflammatory activity 
leads to the development of insulin resistance and hypertension in 
obese individuals. 
             Adiponectin is an important cytokine produced by the 
adipose tissues has anti-inflammatory property, through which it 
plays a key role in increasing the insulin sensitivity. Also through 
its protective effect over the vascular endothelium, reduces risk of 
development of hypertension in obese persons. 
              In obesity the adiponectin levels are decreased and along 
with elevated IL-6 level alters the homeostasis between the pro and 
anti-inflammatory cytokines, ultimately increasing the risk for 
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development of insulin resistance and hypertension in these 
individuals. 
In the present study obese individuals with and without 
hypertension, who fulfilled the criteria for the study was selected.  
Serum interleukin-6 levels were measured and compared with their 
insulin resistance status and hypertension. 
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                                    AIMS AND OBJECTIVES 
 
            1. To do serum Interleukin-6 in obese persons. 
 
             2.To  find  the  correlation  between  serum  Interleukin -6  levels                                                 
with   Insulin  resistance  and Hypertension  in  obesity. 
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Obesity has been considered as a medical disorder right from the ancient 
period in the evolution of human being. 
The Greek were the first to recognize obesity as a medical disease. 
Hippocrates wrote that “corpulence is not only a disease itself, but the 
harbinger of others”. 
The Indian surgeon Sushrutha (6th century BC) related obesity to diabetes 
and various disorders of cardiovascular system. 
OBESITY AND INFLAMMATION 
The concept of metabolic syndrome postulates that tissue resistance to 
insulin is the core mechanism underlying the co-occurrence of multiple 
metabolic risk factors i.e., central obesity, hyper insulinaemia, glucose 
tolerance and hypertension
1
. 
The adipose tissues of the body release many anti inflammatory and pro 
inflammatory cytokines into the body. 
Adiponectin is an important anti-inflammatory cytokine which is 
synthesized from the adipocytes which increases the activity of insulin. In 
10 
 
liver it inhibits gluconeogeneis. In muscles it increases the glucose 
uptake. 
In insulin resistance status plasma adiponectin levels are low from either 
obesity or lipodystrophy and adiponectin treatment improves insulin 
action and the metabolic disturbances associated with insulin resistance 2. 
In obesity, due to the low levels of adiponectin these occurs an imbalance 
between the adiponectin and other pro inflammatory cytokines, which 
leads to series of metabolic consequences which leads to insulin 
resistance. 
INTERLEUKIN-6 AND OBESITY 
Numerous pro inflammatory cytokines are produced from the adipose 
tissue in obesity. Important among them are IL-1, IL-6, resistin, TNF-α, 
and  
c-reactive protein. 
Among these interleukin-6 (IL-6) is an important pro inflammatory 
cytokine which though various mechanism induce insulin resistance in 
patients with obesity. 
11 
 
Interleukin 6 (IL-6) originally denoted as a protein secreted by 
leucocytes, is now recognized to be produced by non-immune cells as 
well 
3
. 
More than one third of the circulating IL-6 is produced from the adipose 
tissue 4. 
The abdominal visceral obesity facilitates the pro inflammatory cytokines 
which are produced from the adipose tissue, a direct access to the liver 
through the portal vein. 
INSULIN RESISTANCE AND IL-6 
Various mechanisms have been postulated, by which IL-6 produces the 
insulin resistance status in peoples with obesity. 
Insulin plays a vital role in glucose metabolism by its various effects such 
as increasing the uptake of glucose by the skeletal muscle and adipose 
tissue, promoting hepatic glycogen synthesis, inhibiting the 
gluconeogenesis by the liver and kidney. 
Insulin mediates all the action though its interaction with its receptors and 
activating Tyrosine kinase, which is followed by auto phosphorylation 
and through which insulin receptor substrates activities are augmented. 
12 
 
IL-6 reduces the activity of insulin signaling molecule 
5
. 
IL-6 induces the expression of suppressor of cytokine signaling 3 (SOCS-
3) which then leads to the impairment of insulin action 
6
. 
Insulin resistance may be considered as an early marker for the risk of 
development Type-II Diabetes mellitus in people who are obese. 
Insulin resistance status if not intervened may procede to the next stage of 
pre diabetes in obese individuals. 
At this stage, life style modification and weight reduction measures may 
attenuate the disease progression other ways these individuals may 
develop Type-II diabetes mellitus. 
Adipose tissue IL-6 expression and the circulating IL-6 expression are 
increased in obese individuals are positively correlated with insulin 
resistance and the levels decrease following weight loss 
7
. 
IL-6 has numerous other actions in the body apart from mediating insulin 
resistance. 
13 
 
When infection or trauma occurs to the body, T-cells and macrophages 
secrete IL-6 though which Immune response is stimulated and 
inflammation occurs. 
IL-6 also has significant activity in skeletal muscle. When secreted by 
muscles called as myokines there, which levels are increased after 
exercise. IL-6 promotes the substrate delivery to the exercising muscle 
from extracellular substates 
8
. 
This is one of the mechanism which says IL-6 also has anti-inflammatory 
role. 
In blood vessels IL-6 exerts mainly a pro inflammatory effect. Smooth 
muscle cells of tunica media of many blood vessels secrete IL-6. 
IL-6 is the most important mediator of fever in the body. It has the 
capability of crossing the blood brain barrier and reaches the 
hypothalamus where it initiates the synthesis of PGE2
9
. 
This PGE2 secreted in the hypothalamus mediates the alteration of body 
temperature. 
14 
 
IL-6 exerts its effect through its interaction with its two types of trans 
membrane glycoprotein receptors. One is GP 130/CD 130 receptor and 
the other one is R/GP 80/CD 126 receptor. 
In bones osteoblasts are the main cells which secrete IL-6. The effect of 
IL-6 in bone is the stimulation of osteoclast formation. 
IL-6 is an important mediator of acute phase protein synthesis. Regarding 
immune system it increases production of neutrophils, promotes growth 
of B cells and antagonizes regulatory T-cell action. 
In obesity, the increased level of adipose tissue which secretes the 
inflammatory cytokines leads to the development of insulin resistant 
status. 
 
 
   INSULIN RESISTANCE-CAUSES 
Apart from obesity, if other causes of insulin resistance are considered, 
the developmental origin of Insulin resistance is an important one. 
15 
 
A relationship between low birth weight and development of insulin 
resistance status has been established 
10
. 
When there is maternal malnutrition or placental abnormalities it leads to 
malnutrition of the fetus and low birth weight. 
Low birth weight compromises the development of various vital organs 
of the body which leads to organ malfunction, insulin resistance, 
abnormal vascular development and decreased nephron number etc. 
Next important consideration in insulin resistance is the genetic cause. 
Rare form  of  genetic  mutuation  have been identified in the glucokinase 
gene which are associated with insulin resistance and low birth weight 
11
. 
When the insulin resistance is genetically determined, the fetus becomes 
resistant to insulin like growth factor, which leads to reduced fetal growth 
and low birth weight. 
Maternal dietary habits also influences the fetal growth and over its future 
insulin response status. 
Another important study is the relation between the breast feeding and 
future chances of getting obesity. 
16 
 
Breast feeding acts to protect against obesity, due to lower protein and 
total energy intake when compared to the bottle fed infants
12
. 
Mutuations in the insulin receptors may also lead to a state of Insulin 
resistance. 
Dietary habits of a person also influence the sensitivity to insulin. A high 
fat diet, particularly foods containing saturated fat plays a key role in the 
development of insulin resistance. 
Insulin resistance is positively correlated with quantity and quality of fat 
intake and it has been negatively correlated with proportion of the dietary 
fibre
13
. 
Sedentary life style is also an important contributing factor for the 
development of insulin resistance status. 
It has been estimated in a study that each 500 Kcal/week increment in 
physical activity related to energy expenditure reduces the life time risk 
of developing type-2 diabetes by 6%
14
. 
At the molecular levels, superoxide dismutase activity abnormalities may 
also lead to insulin resistance. 
17 
 
In this condition the insulin resistance was found to be reversed by 
exposing the cells to inhibitors of electron transport chain inhibitors and 
mitochondrial uncouplers
15
. 
In women with polycystic ovarian disease have been found to be 
associated with insulin resistance particularly in overweight group. 
Previous studies have showed that obesity and PCOS have a separate and 
synergistic relationship with insulin resistance
16
. 
Some of the possible risk factors for developing insulin resistance are 
hypertriglyceridaemia, hepatitis with infections, hypercortisolism and 
drugs like anti retrovirals,  glucocorticoids etc. 
Obesity is a major predisposition factors for various disease states such as 
Insulin Resistance, Diabetes and Hypertension. 
OBESITY 
Obesity can be defined as a state of increased adipose tissue mass in the 
body. 
There is no direct method of measurement of obesity. Hence, it is 
measured by some indirect methods such as 
18 
 
Body mass index (BMI) 
Skin fold thickness 
Densitometry (underwater weighing) 
Using CT or MRI and 
Electrical impedance. 
Commonly used criteria for obesity using BMI followed world wide is 
BMI>30 for obesity and BMI > 40 as Morbid obesity. But there are 
regional or ethnic variations. 
In India the health ministry has revised the criteria for obesity as per the 
suggestion given by the WHO subcommittee report on obesity and 
metabolic syndromes in the Asia pacific region in 2000. 
According to the survey India could become the global capital of diabetes 
around 2050. Hence, it became mandatory for the revision of obesity 
criteria. 
According to the new revised criteria the following are considered. 
BMI > 23/kgm
2
 will be considered as overweight. 
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BMI > 25/kgm
2
 will be considered as obese. 
Waist circumference for 
men > 90 cm 
women > 88 cm 
The above guideline has been jointly released by the Health Ministry, 
Diabetes foundation of India, Indian Council of Medical research, All 
India institute of medical science and national institute of nutrition. 
Normal body weight is regulated by both endocrine and neuronal 
mediated mechanisms which maintain a equilibrium between energy 
intake and expenditure. 
When forced overeating occurs the homeostatic mechanism begins to act 
following which increase in energy utilization and decrease in appetite 
occurs. 
When forced deprivation of food occurs the homeostatic mechanism 
respond in a way to decrease the energy utilization and increase in 
appetite. 
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This adaptive mechanism in the body is mainly mediated by the leptin 
secreted by the adipose tissue. It crosses the blood brain harrier and 
reaches the hypothalamus through which it producing its action. 
Appetite is generally influenced by three important factors such as 
hormones, neural and metabolic products over the hypothalamus. 
Hormones included are insulin, cortisol and gut peptides. Neural 
influences are mediated by the vagal inputs. Metabolites including 
glucose and ketones  can influence the appetite. 
Among the factors which increase the appetite are neuropeptides, melanin 
concentrating hormone, orexin, agouti related peptide and endo 
cannabinnoid. 
The factors which decrease the appetite are melanocyte stimulating 
hormone, cocaine and amphetamines, glucagon related peptide -1, and 
cholecystokinin. 
ENERGY EXPENDITURE 
Next to appetite, energy expenditure plays an important role in the 
homeostasis of maintaining the weight. 
21 
 
Energy expenditure occurs by the following methods. 
Basal metabolic rate or resting state. 
Energy utilized by metabolism and storage of food. 
Exercise induced thermogenic process. 
Thermogenesis by adaptive mechanism. 
Among these mechanism basal metabolic rate plays a major contribution 
to energy expenditure. It is about 70%. Energy expenditure through 
exercise is about 5 to 10%. 
Fat deposit in the body is of two types. Brown adipose tissue and white 
adipose tissue. Adaptive thermogenesis occurs through brown adipose 
tissue for energy expenditure. 
Obesity also commonly runs in families. Many of the monozygotic twins 
reared at different places had same BMI. 
Obesity specific mutant genus have been identified in humans
17
. They are 
Leptin receptor gene. 
Pro-opiomelanocortin gene. 
22 
 
Type 4 receptor of melanocyte receptor gene. 
TrKB- a neutrophil receptor. 
Even though the mutation in these specific genes makes a person 
susceptible, environmental factors have a key role in development of 
obesity, as evidenced by the fact that famine prevents obesity even in the 
most obese prone individual. 
SYNDROMES WITH OBESITY 
Human syndromes with defined inheritance are, prader-willi syndrome 
where deletion of IBQ 11-13 chromosome occurs and manifests as 
obesity, associated with mental retardation and hypogonadism. 
In Bardet Biedl syndrome obesity is associated with mental retardation, 
retinitis pigmentosa, diabetes and cardiac malformations. 
There are some other specific syndromes where people will present with 
obesity. 
In Cushing’s syndrome patient has obesity, hypertension and gluose 
intolerance. Here obesity may be due to local reactivation of cortisol in 
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fat by 11B-hydroxy steroid de-hydrogenase 1, an enzyme that converts 
inactive cortisone to cortisol. 
Hypothyroidism, an uncommon cause of obesity can be easily ruled by 
measuring the levels of thyroid stimulating hormone. 
Patients with insulinoma also present with obesity, which is mainly due to 
over eating which occurs to prevent hypoglycaemia. 
Many intracranial pathology such as tumours, trauma & inflammation  
causes abnormal activation of hunger or satiety centre may also result in 
obesity. It can also cause decrease in growth hormone levels the one 
which has lipolytic activity, deficiency of this hormone may lead to 
obesity. 
Adipose tissue is made up of adipose cell which has lipid storing function 
and a stromal/vascular compartment consisting of preadipocytes and 
macrophages.  
In obesity, adipose mass increases which is also associated with an 
increased in macrophage population. 
CYTOKINES IN OBESITY 
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These adipose tissue produces various cytokines and adiponectins. 
The cytokines produced are  
energy balance regulatory hormone leptin  
Tumour necrosis factor α. 
Interleukin-6  
Factor - D (adipsin) 
Plasminogen activator -1 
The functions of adiponectins are, enhancing insulin sensitivity, lipid 
oxidation and vascular protective effect. 
Resistin and IL-6 are the cytokines which produces insulin resistance 
status
18
. 
OBESITY AND HYPERTENSION 
Next to Insulin resistance hypertension is the important consequence of 
obesity. 
Hypertension has become one among the leading cause of mortality and 
morbidity in patients with obesity. 
Blood pressure may be classified as  
25 
 
 Systolic, mm of Hg Diastolic mm of Hg 
Normal <120 <80 
Pre-hypertension 120-139 80-89 
Stage-1 Hypertension 140-159 90-99 
Stage-2 Hypertension >160 >100 
Isolated systolic hypertension >140 <90 
In obesity various mechanisms have been postulated for the development 
of hypertension. 
Inflammatory cytokines IL-6 elevation and reduction in anti-
inflammatory mediator adiponectin are being the major cause in 
development of hypertension in obese persons. 
Adiponectin is secreted from the adipose tissue. In obesity due to increase 
in visceral adiposity the plasma levels of adiponectins are markedly 
reduced
19
. 
ADIPONECTIN 
Adiponectin has the following properties though which it exerts a strong 
anti hypertensive effects. 
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Enhanced endothelium dependent and non dependent vasodialation. 
Suppression  of  atherosclerosis. 
Suppression οf vascular adhesion molecule scavenger receptors. 
Reduces the levels of TNF-α and there by its inflammatory effects over 
endothelium. 
Attenuation of growth factor effects on smooth muscle cells. 
Enhanced Nitric oxide production  
Stimulation of angiogenesis. 
Reduction of neoinitimal thickening and proliferation of smooth muscle 
cells in mechanically injured  arteries. 
Inhibition of endothelial cell proliferation and migration. 
Inhibition of hypertrophic myocardial signaling 
HYPERTENSION AND IL-6 
IL-6 secreted by the adipose tissue also play an role in the development 
of hypertension in obese individuals. 
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The association between hypertension and inflammation indicate that IL-
6 plays a role in angiotensin-II mediated hypertension
20
. 
The renin-angiotensin-aldosterone system mediates its effect over the 
blood pressure through the vasocostrictor effect of angitensin-II and 
capability of aldosterone to retain sodium in the body. 
There are three main stimulation for renin secretion. 
In thick ascending loop of henle when the delivered sodium load is low. 
When the afferent arteriole of the kidney sense the reduction in the stretch 
though is baroreceptor mechanism. 
When the renin secreting cells are stimulated by the sympathetic neurons  
through β1 adrenoceptors. 
Once released into the circulation the renin cleaves  the angiotensinogen 
into Angiotensin-I. 
Angiotensin-I is then converted into angiotensin-II by angiotensin 
converting enzyme, which also catalyses the conversion of bradykenin to 
inactive peptide. 
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Angiotension II produces its effect mainly through the receptor suptypes 
AT1 receptor and AT2 receptor. 
When AT1 receptor is stimulated it produces strong pressure effect 
through sympathetic stimulation. AT1, receptor stimulation also leads to 
increased secretion of aldosterone by the Zona glomerulosa. 
Aldosterone mainly exerts its action in the distant convoluted tubule by 
increasing the sodium reabsorbtion and thereby creating the pressure 
response in the blood vessels. 
ENDOTHELINS AND IL-6  
IL-6 also play a significant role in enhancing the formation of endothelial 
cell derived substances such an endothelin through which it mediates the 
hypertensive effect21. 
Endothelium are proteins which has vasoconstictor effect on blood 
vessels. They are produced mainly by the endothelium and also has an 
vascular homeostasis role. 
Among the two types of endothelin receptors actions which are mediated 
through endothelin A type receptor contributes to the vasopressor effect. 
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NITRIC OXIDE SYNTHASE AND IL-6 
IL-6 also increase the half life  of caveolin-1 and facilitates it’s binding to 
endothelial nitric oxide synthetase and thereby decreasing  the production 
of nitric oxide production through which it mediates its hypertensive 
effect22. 
Nitric oxide (NO) is an important cell signaling molecule which has a 
powerful vasodialator effect. 
Various methods are available for the calculation of insulin resistance. 
They are as follows: 
Euglycaemic insulin clamp method. 
Homoeostatic model assessment of insulin resistance (HOMA-IR) 
Quantitative insulin check index (Quicki)  
Fasting insulin / glucose ratio (FIGR) 
Insulin sensitivity index 
Triglyceride / High density lipid ratio (TG/HDL) 
The specificity and sensitivity varies among these methods. 
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Euglycaemic clamp method is the gold standard for calculating insulin 
resistance. 
In a comparative study, with the remaining methods, highest specificity 
(97.6%) and sensitivity (92.6%) for HOMA and QUIKI methods were 
found in predicting the insulin resistance23. 
LEPTINS AND OBESITY 
Leptin is one of the important cytokine produced by the adipose tissue 
and plays a key role in regulating energy intake and expenditure. 
The plasma levels of leptin are highly correlated with adipose tissue 
mass, their levels are increased in obese persons, decreased after losing 
weight
24
. 
Human leptin is produced by primarily produced by the adipocytes tissue 
of white adipose tissue (WAT). It has 167 amino acids. Small 
contribution is also from brown adipose tissue (BAT). 
Main action of leptin is in the hypothalamus where it suppresses the 
appetite. This effect is done by counteracting the effects of neuropeptide 
and anandamide, also by promoting the synthesis of α-MSH. 
31 
 
It has been found that cognitive control of food intake occurring with low 
circulating levels of leptin is reversed by administration of leptin
25
. 
RESISTINS 
Resistins also known as adipose tissue specific factor is another important 
inflammatory cytokine produced in obesity. 
The role of Resistins in the development of obesity, and insulin resistance 
are inconclusive except for their raised levels in obesity26. 
Resitins play an established role in dyslipidaemia. It increases the 
production of LDL in liver. It also degrades the LDL receptors in the 
liver, by which it decrease the clearance of LDL. 
Resistins accelerates the deposition of LDL in the arterial wall and 
thereby increasing the risk for cardiovascular disease. It also opposes the 
effect of statins, the drug mainly used for lipid lowering activity in cardio 
vascular diseases
27. 
 
TUMOUR NECROSIS FACTOR-α 
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Tumor necrosis factor α (TNF-α) produced by the adipose tissue is 
implicated in the pathogenesis of metabolic syndrome
28
. 
It is also known as cachexins produced primarily by the activated 
macrophages and also by other cell types like CD
4
 lymphocyte and NK 
cells.  
Primary function of TNF-α is the regulation of immune cells, they also 
lake part in the systemic inflammation and in acute phase reaction. 
In obesity, there is an increase production of TNF-α from the 
macrophages in the adipose tissue, and they play an important role in the 
development of insulin resistance in these individuals. 
In liver TNF-α promotes the serine phosphorylation of insulin receptor 
substrate 1, and thereby impairing the insulin signaling which leads to a 
insulin resistance status. 
MACROPHAGE AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 
(MCP-1) 
Macrophage and monocyte chemoattractant protein-1 (MCP-1) is also an 
inflammatory cytokine produced by the adipose tissue. 
33 
 
This cytokine has both paracrine and endocrine functions. The main 
action of this cytokine is the impairment of insulin receptor 
phosphorylation and inhibition of insulin mediated glucose uptake by the 
adipose. cells
29
 
PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)  
Plasminogen activator inhibitor-1 (PAI-1) is a member of serine protease 
inhibitor group that has an inhibitory effect on fibrinolytic system, 
thereby reducing intravascular thrombolysis by inactiviating urokinase 
and tissue plasminogen activation. 
In obesity individuals, the visceral adipose tissue serves as a major source 
of PAI-1. Their elevation in this condition association has been positively 
correlated with insulin resistance and hypertriglyceridaemia30. 
OBESITY COMPLICATIONS 
Obesity mediated complications involves many systems in the human 
body, increasing the risk of their morbidity and mortality. 
Ischemic heart disease, myocardial infarction, congestive heart failure, 
high blood pressure, abnormal cholesterol levels, deep vein thrombosis 
34 
 
and pulmonary embolism are the cardiovascular complication that can be 
mediated or augmented by obesity. 
Diabetes mellitus, polycystic ovarian disease, infertility, complications 
during pregnancy, menstural disorder, intra uterine fetal death and birth 
defects are the common endocrinal disorders associated with obesity. 
Gouty arthritis, osteoarthritis, poor mobility and low back ache are some 
orthopedic conditions usually related to obesity. 
Regarding central nervous system stroke, meralgiaparesthetica, dementia, 
carpal tunnel syndrome, multiple sclerosis, migraine are some of the 
conditions attributed to obesity. 
Depression particularly in women and social stigmatizations are the 
common psychiatric conditions related to obesity. 
Acanthosis nigricans, stretchmarks, cellulitis, hirsutism, intertrigo are the 
common dermatological problems in obesity. 
Obstructive sleep apnea, obesity, hypoventilation syndrome, gastro 
eosophageal reflux disease, fatty liver, sexual dysfunction, hypogonadism  
are the other illness  related to obesity. 
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LIPID PROFILE 
In obesity the lipid profile of the individuals are also altered which also 
leads to many disorders. 
The normal lipid profile is as follows, as per American Heart Association. 
Serum cholesterol -  Normal up to 200mgs/dl 
 Borderline up to 239 mg/dl 
 >240mg/dl elevated 
HDL cholesterol -  30-60 mgs/dl 
LDL cholesterol -  100-190 mg/dl  
 >190 mg/dl 
Serum TGL         -  <150 mg/dl. 
TGL value vary depending on diet, alcohol, metabolic state, exercise, 
elevation is considered only when repeated value are high. 
Acylcoenzyme A diacyl glycerol acyltransferase - 1 (DGAT-1) acts as a 
key enzyme in the synthesis of TGL, which is the main storage form of 
excess caloric fat. It’s over expression in obesity causes increases levels 
of TGL
31
. 
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Based on medical conditions which cause morbidity and mortality in 
obese individuals, makes it as an important disease which should be 
treated. 
The goal of therapy in treating obesity must be, treat to improve the 
obesity related co-morbid illness and reducing the risk of development of 
future co-morbid illness. 
Lifestyle modification is the important initial step of treatment of obesity, 
consists of dietary intervention, physical activity and behavioural 
modification. 
Regarding dietary intervention a very low fat diet <10 percent fat, 
vegetarian food, along with cessation of smoking and moderate exercise 
was helpful in reducing weight as well as improvement in coronary 
angiographic parameter
32
. 
Regarding physical activity when combined with dietary measures yields 
a good result. 
The 2008 physical activity guidelines for American recommends that 
adults should  engage 150 minutes  in a week with moderate - intensity 
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activity or 75 minutes of vigorous activity performed in 10 mts episode 
distributed over a week. 
Cognitive behavioral therapy haps to adhere to the reinforced dietary and 
physical activity. It consists of stress management, stimulus control and 
problem solving.  
Pharmacotherapy for obesity include various classes such as centrally 
acting anorexiants (e.g.) Sibutramine, which acts as serotonin and 
noradrenalin reuptake inhibitor. 
Peripherally acting drugs (e.g.) orlistat which is a potent, slowly 
reversible inhibitor of   pancreatin, gastrin, corboxylester and 
phospholipaseA2. 
Surgical intervention in treatment of obesity can be considered in case of 
morbid obesity (BMI > 40kg/m
2
) or in those with moderate obesity (BMI 
>35 kgm
2
) with serious medical conditions. 
Restrictive surgeries which limit the amount of food that stomach can 
hold and slow the gastric emptying. Restrictive - malabsorbtive surgeries 
can be done for restriction and selected malabsorbtion. 
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Obesity having a definite role in insulin resistance and cardiovascular 
disease needs a thorough evaluation and treatment to lead a better life.  
 
 
 
 
 
 
 
 
 
 
     MATERIALS AND METHODS 
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          MATERIALS AND METHODS: 
The center of study is institute of internal medicine, madras medical 
college &Rajiv Gandhi government general hospital, Chennai -3 
Study design      : cross sectional study. 
Venue                 : Rajiv Gandhi government general hospital, Chennai. 
 
Collaborating departments: 
Institute of Biochemistry, MMC &RGGGH, Chennai -3. 
Duration          : Study was conducted from June 2012 to November 2012. 
About fifty obese patients who attended our hypertension outpatient 
department and general medical out Patient  department with obesity 
related complaints such as weight gain, social stigma regarding obesity 
and obese hypertensive’s  who came for getting drugs were selected 
randomly. A complete history was taken including past history diabetes, 
hypertension, coronary artery disease, thyroid disorders and COPD. 
His/Her personal habits were enquired. 
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A complete physical examination was done with recording of vitals 
(temperature, pulse rate, and Blood pressure). A battery of blood 
investigations were done including renal function test, complete blood 
count, liver function test, urine analysis, HbA1c,Fasting blood sugar, and 
ECG were  done. Based on the results fifty patients who fulfilled the 
inclusion criteria were selected. Fasting insulin was done insulin 
resistance was calculated. 
Insulin resistance was calculated by Homeostatic model assessment of 
insulin resistance [HOMA-IR] method.Reference value=1 
                  Fasting blood glucose (mg/dl) × Fasting plasma insulin  
HOMA-IR=  
                                            405 
        Serum Interleukin-6 level   was done by Genprobe Diaclone ELISA 
method  for them. Up to a  value of 2 is kept as normal. 
 INCLUSION CRITERIA  
1. Age-20 to 35  years   with  BMI  greater  to  27  kg/m2  with  and  without  
hypertension. 
2. Non diabetics.  
3. Nonsmoker. 
4. No pregnancy. 
41 
 
 EXCLUSION CRITERIA 
1. Hypothyroidism. 
2. Renal disease. 
3. Liver disorders. 
STASTITICAL ANALYSIS PLAN 
Data analysed using statistical package –SPSS Software. 
CONSENT 
All participants gave written informed consent. 
ETHICAL COMMITTEE APPROVAL 
Institutional Ethics Committee of Madras Medical College approved the 
study. 
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       OBSERVATION AND RESULTS 
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                    GENDER DISTRIBUTION 
Gender distribution of the 50 patients selected randomly for the study was 
29 males and 21 females. 
                                            TABLE-1 
    SEX NUMBER 
OF PATIENTS 
PERCENTAGE 
MALE 29 58% 
FEMALE 21 42% 
 
 
 
MALE
58%
FEMALE
42%
SEX
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                               AGE DISTRIBUTION 
The age of the patients selected for the study ranged from 25 years to 
35Years. 
TABLE-2 
Age of the patient   No. of patients Percentage 
26-28 years 12 24% 
29-31 years 13 26% 
31-35 years 25 50% 
                             
0%
5%
10%
15%
20%
25%
30%
26-28 29-31 32-35
AGE
AGE
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DISTRIBUTION OF THE  WEIGHT OF THE PATIENTS 
              The weight of the 50 numbered study population ranged from 80 
to 101 kilograms. 
TABLE-3 
Weight of the patients 
[kgms] 
     No. of patients        Percentage 
           60-70                    9             18% 
           71-80                   22             44% 
           81-90                   13             26% 
           91-100                     5             10% 
   More than 100                     1                2% 
46 
 
 
                                WAIST CIRCUMFERENCE  
The waist circumference among the 50 numbered study population 
ranged from 80 to 101 cms. 
Table shows the distribution waist circumference of the patients studied 
Waist No.of patients Percentage 
80-90 13 26% 
91-100 28 56% 
>1oo 9 18% 
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                    BODY MASS INDEX DISTRIBUTION 
Body mass distribution among the 50 numbered study group ranged from 
29.0 to 35.2. TABLE-5 
Body mass index No.of Patients Percentage 
27.0 to 29.0 13 26% 
29.1 to 31.0 19 38% 
31.1 to 33.0 10 20% 
33.1 to 35.0  7 14% 
>35.0 1 2% 
0%
10%
20%
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40%
50%
60%
80-90 91-100 >100
waist
waist
48 
 
 
GENDER DISTRIBUTION OF HYPERTENSIVE 
PATIENTS 
          For the study group of 50 obese individuals,25 persons with obesity 
alone and another 25 with obesity and hypertension were selected. 
Gender  distribution  among  the 25 numbered hypertensive obese 
patients  is shown in the Table-6. 
sex Hypertension patients Percentage 
Male 13 52% 
Female 12 48% 
0%
5%
10%
15%
20%
25%
30%
35%
40%
27-29 29.1-31 31.1-33 33.1-35 >35
BMI
BMI
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                        INSULIN RESISTANCE  
Based  on control values 36 patients among study population of 50 had 
insulin resitance. 
Gender   No.of Patients Insulin resistance Percentage 
Male 29 19 65.51% 
Female 21 17 80.95% 
Total 50 36 72% 
 
52%
48%
HYPERTENSION
Males
Females
50 
 
 DITRIBUTION OF INSULIN RESISTANCE 
 
GENDER DISTRIBUTION OF INSULIN RESISTANCE 
Among the study group 50 patients ,36 patients had insulin resistance.out 
of the 36 patients 19 were males and 17 were female patients. 
                                     TABLE-8 
Gender   No.of Patients Insulin resistance Percentage 
Male 29 19 65.51% 
Female 21 17 80.95% 
 
72%
28%
Insulin Resistance
Insulin Resistance
Normal
51 
 
GENDER DISTRIBUTION OF INSULIN RESISTANCE 
 
HYPERTENSION AND INSULIN RESISTANCE 
In the study group 25 had both obesity and hypertension.Among these 25 
patients had insulin resistance. 
                                                        TABLE-9 
No.of Hypertension 
patients 
Hypertension with 
Insulin Resistance 
Percentage 
25 20 80% 
44%
45%
46%
47%
48%
49%
50%
51%
52%
53%
Males Females
Insulin resistance -Gender Distribution
Insulin resistance
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DISTRIBUTION OF INSULIN RESISTANCE IN OBESE 
HYPERTENSIVES 
             
 
                             Weight and Insulin resistance 
80%
20%
Insulin Resistance and Hypertension
HT with IR
HT Without IR
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                      Chi square test 
   Value        df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 6.720(a) 6 .347 
Likelihood Ratio 7.031 6 .318 
Linear-by-Linear 
Association 
.902 1 .342 
N of Valid Cases 50     
          
                         P value = 0.347. NOT SIGNIFICANT.  
 
                                        
Weight
> 10091-10081-9070-80
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> 2
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                                       GENDER AND IR 
 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 1.582(a) 2 .453 
Likelihood Ratio 1.622 2 .444 
Linear-by-Linear 
Association 
.627 1 .428 
N of Valid Cases 50     
                                P value =1.58.Not significant 
Sex
FemaleMale
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             BODY MASS INDEX AND INSULIN RESISTANCE 
 
      
   Value       Df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 7.303(a) 2 .026 
Likelihood Ratio 7.568 2 .023 
Linear-by-Linear 
Association 
6.504 1 .011 
N of Valid Cases 50     
 
P value 0.026. significant 
BMI
31-3527-30
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                                          BMI   and IR. 
 
   
IR 
   Total     <= 1      1-2      > 2 
BMI 27-30 Count 10 12 4 26 
% within 
BMI 
38.5% 46.2% 15.4% 100.0% 
% within 
IR 
71.4% 60.0% 25.0% 52.0% 
31-35 Count 4 8 12 24 
% within 
BMI 
16.7% 33.3% 50.0% 100.0% 
% within 
IR 
28.6% 40.0% 75.0% 48.0% 
Total Count 14 20 16 50 
% within 
BMI 
28.0% 40.0% 32.0% 100.0% 
% within 
IR 
100.0% 100.0% 100.0% 100.0% 
                          
                            P value =o.026 .SIGNIFICANT  
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WAIST CIRCUMFERENCE AND INSULIN 
RESISTANCE 
  
                                           Chi square test 
 value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 10.609(a) 4 .031 
Likelihood Ratio 10.080 4 .039 
Linear-by-Linear 
Association 
3.873 1 .049 
N of Valid Cases 5     
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                P value = 0.031 SIGNIFICANT 
             
            WAIST AND INSULIN RESISTANCE 
 
. 
   
IR 
Total      <= 1      1-2     > 2 
Waist 80-90 Count 4 6 3 13 
% within 
Waist 
30.8% 46.2% 23.1% 100.0% 
% within 
IR 
28.6% 30.0% 18.8% 26.0% 
91-100 Count 9 13 6 28 
% within 
Waist 
32.1% 46.4% 21.4% 100.0% 
% within 
IR 
64.3% 65.0% 37.5% 56.0% 
> 100 Count 1 1 7 9 
% within 
Waist 
11.1% 11.1% 77.8% 100.0% 
% within 
IR 
7.1% 5.0% 43.8% 18.0% 
Total Count 14 20 16 50 
% within 
Waist 
28.0% 40.0% 32.0% 100.0% 
% within 
IR 
100.0% 100.0% 100.0% 100.0% 
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                 W/H  RATIO AND INSULIN RESISTANCE       
 
          
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 9.280(a) 2 .010 
Likelihood Ratio 8.893 2 .012 
Linear-by-Linear Association 7.916 1 .005 
N of Valid Cases 50     
                           
                                 P value=0.0410.SIGNIFICANT 
 
W/H
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   IR Total 
    <= 1 1-2 > 2   
W/H <= 1 Count 7 3 1 11 
    % within W/H 63.6% 27.3% 9.1% 100.0% 
    % within IR 50.0% 15.0% 6.3% 22.0% 
  > 1 Count 7 17 15 39 
    % within W/H 17.9% 43.6% 38.5% 100.0% 
    % within IR 50.0% 85.0% 93.8% 78.0% 
Total Count 14 20 16 50 
  % within W/H 28.0% 40.0% 32.0% 100.0% 
  % within IR 100.0% 100.0% 100.0% 100.0% 
W/H N Mean Std. Deviation Std. Error Mean 
IL6 <= 1 11 3.182 .7319 .2207 
  > 1 39 4.879 1.8192 .2913 
 
 
 W/H N Mean Std. Deviation 
Std. Error 
Mean 
IIL6 <= 1 11 3.182 .7319 .2207 
  > 1 39 4.879 1.8192 .2913 
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                        LDL AND IL-6 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square   4.212(a) 2 .122 
Likelihood Ratio     4.943 2 .084 
Linear-by-Linear 
Association 
    3.604 1 .058 
N of Valid Cases         50     
P value =0.012. NOT SIGNIFICANT 
LDL
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   IR Total 
    <= 1 1-2 > 2   
LLDL < 100 Count 5 6 1 12 
    % within LDL 41.7% 50.0% 8.3% 100.0% 
    % within IR 35.7% 30.0% 6.3% 24.0% 
  >= 100 Count 9 14 15 38 
    % within LDL 23.7% 36.8% 39.5% 100.0% 
    % within IR 64.3% 70.0% 93.8% 76.0% 
Total Count 14 20 16 50 
  % within LDL 28.0% 40.0% 32.0% 100.0% 
  % within IR 100.0% 100.0% 100.0% 100.0% 
 
             LDL AND IL-6 
 LDL N Mean Std. Deviation 
Std. Error 
Mean 
IL6 < 100 12 3.850 1.4152 .4085 
  >= 100 38 4.713 1.8529 .3006 
                           P value -0.14. Not Significant 
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                                  TGL AND IR 
            
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 34.083(a) 2 .000 
Likelihood Ratio 43.913 2 .000 
Linear-by-Linear Association 30.287 1 .000 
N of Valid Cases 50     
P value =0.00.SIGNIFICANT 
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   IR Total 
    <= 1 1-2 > 2   
TGL < 150 Count 14 5 0 19 
    % within TGL 73.7% 26.3% .0% 100.0% 
    % within IR 100.0% 25.0% .0% 38.0% 
  >= 150 Count 0 15 16 31 
    % within TGL .0% 48.4% 51.6% 100.0% 
    % within IR .0% 75.0% 100.0% 62.0% 
Total Count 14 20 16 50 
  % within TGL 28.0% 40.0% 32.0% 100.0% 
  % within IR 100.0% 100.0% 100.0% 100.0% 
                 TGL AND IL-6 
 TGL N Mean Std. Deviation Std. Error Mean 
IL6 < 150 19 2.974 .5772 .1324 
  >= 150 31 5.445 1.6114 .2894 
             
 P value=0.00.SIGNIFICANT  
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SYSTEMIC HYPERTENSION AND IL-6 
 
 
                                    SHT AND IR 
 Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 3.193(a) 2 .203 
Likelihood Ratio 3.238 2 .198 
Linear-by-Linear 
Association 
.131 1 .717 
N of Valid Cases 50     
 
                           P value=0.20.Not significant 
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   IR Total 
    <= 1 1-2 > 2   
HT Yes Count 5 13 7 25 
    % within HT 20.0% 52.0% 28.0% 100.0% 
    % within IR 35.7% 65.0% 43.8% 50.0% 
  No Count 9 7 9 25 
    % within HT 36.0% 28.0% 36.0% 100.0% 
    % within IR 64.3% 35.0% 56.3% 50.0% 
Total Count 14 20 16 50 
  % within HT 28.0% 40.0% 32.0% 100.0% 
  % within IR 100.0% 100.0% 100.0% 100.0% 
 
                                               HT AND IL-6 
 HHT N Mean Std. Deviation 
Std. Error 
Mean 
IIL6 Yes 25 5.216 1.8694 .3739 
  No 25 3.796 1.3960 .2792 
 
                   P value=0.004. SIGNIFICANT 
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                                  LDL AND HT                          
 
 
 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 1.754(b) 1 .185     
Continuity 
Correction(a) 
.987 1 .321     
Likelihood Ratio 1.781 1 .182     
Fisher's Exact Test       .321        .160 
Linear-by-Linear 
Association 
1.719 1 .190     
N of Valid Cases 50         
 
               P value =0.160. Not significant 
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                                WEIGHT AND HT 
 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 6.367(a) 3 .095 
Likelihood Ratio 8.686 3 .034 
Linear-by-Linear Association 1.239 1 .266 
N of Valid Cases 50     
                      P value= .095. Not significant 
Weight
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Descriptives of weight  
                       
       N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
          Lower Bound Upper Bound 
80-90     13 4.062 1.3562 .3761 3.242 4.881 
91-100     28 4.239 1.5763 .2979 3.628 4.851 
> 100       9 5.978 2.3086 .7695 4.203 7.752 
Total     50 4.506 1.7834 .2522 3.999 5.013 
                                
                                 Descriptives of IL-6 
 
 
Sum of 
Squares df Mean Square F        Sig. 
Between Groups 24.055 2 12.028 4.289        .019 
Within Groups 131.793 47 2.804     
Total 155.848 49       
P value =.019.Significant 
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                                      BMI AND HT 
 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .321(b) 1 .571     
Continuity Correction(a) .080 1 .777     
Likelihood Ratio .321 1 .571     
Fisher's Exact Test       .778 .389 
Linear-by-Linear Association .314 1 .575     
N of Valid Cases 50         
                         P value =.58. Not significant 
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                             WAIST AND HT 
 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 3.066(a) 2 .216 
Likelihood Ratio 3.136 2 .208 
Linear-by-Linear 
Association 
2.893 1 .089 
N of Valid Cases 50     
                         P value= .21. Not significant. 
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                              W/H RATIO AND HT 
 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .117(b) 1 .733     
Continuity Correction(a) .000 1 1.000     
Likelihood Ratio .117 1 .733     
Fisher's Exact Test       1.000 .500 
Linear-by-Linear Association .114 1 .735     
N of Valid Cases 50         
P value =.50. not significant 
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                              TGL AND HT 
 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 1.754(b) 1 .185     
Continuity Correction(a) .987 1 .321     
Likelihood Ratio 1.781 1 .182     
Fisher's Exact Test       .321 .160 
Linear-by-Linear Association 1.719 1 .190     
N of Valid Cases 50         
                  P Value=.18. NOT SIGNIFICANT 
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                        GENDER AND HT 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .739(b) 1 .390     
Continuity 
Correction(a) 
.328 1 .567     
Likelihood Ratio .741 1 .389     
Fisher's Exact Test       .567 .284 
Linear-by-Linear 
Association 
.724 1 .395     
N of Valid Cases 50         
                 P value =.39.Not Sisnificant 
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                   IR AND IL-6 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 102.375 2 51.187 44.991        .000 
Within Groups 53.473 47 1.138     
Total 155.848 49       
 
P Value=0.00 SIGNIFICANT 
 
 
Multiple comparisons :- Dependable variation of IL-6 
(I) IR (J) IR 
Mean 
Difference 
(I-J) Std. Error Sig. 95% Confidence Interval 
          Lower Bound Upper Bound 
<= 1 1-2 -1.406(*) .3717 .001 -2.306 -.507 
  > 2 -3.640(*) .3904 .000 -4.585 -2.695 
1-2 <= 1 1.406(*) .3717 .001 .507 2.306 
  > 2 -2.234(*) .3578 .000 -3.100 -1.368 
> 2 <= 1 3.640(*) .3904 .000 2.695 4.585 
  1-2 2.234(*) .3578 .000 1.368 3.100 
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         Multiple comparisons:- waist circumference 
(I) Waist (J) Waist 
Mean 
Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
80-90 91-100 -.178 .5620 .946 -1.538 1.182 
> 100 -1.916(*) .7261 .030 -3.674 -.159 
91-100 80-90 .178 .5620 .946 -1.182 1.538 
  > 100 -1.738(*) .6416 .025 -3.291 -.186 
> 100 80-90 1.916(*) .7261 .030 .159 3.674 
  91-100 1.738(*) .6416 .025 .186 3.291 
Homogeneous Subsets-IL-6 
 
IR N Subset for alpha = .05 
    1 2 3 
<= 1 14 2.779     
1-2 20   4.185   
> 2 16     6.419 
Sig.   1.000 1.000 1.000 
 
 N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
80-90 13 4.062 1.3562 .3761 3.242 4.881 
91-100 28 4.239 1.5763 .2979 3.628 4.851 
> 100 9 5.978 2.3086 .7695 4.203 7.752 
Total 50 4.506 1.7834 .2522 3.999 5.013 
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DISCUSSION 
In obesity the excess adipose tissue particularly from the 
viscera secretes a number of pro-inflammatory 
mediators. These mediators are main causative factors 
for the development of metabolic syndrome obese 
individuals. 
In this context we evaluated the correlation between 
Insulin resistance and systemic hypertension with serum 
IL-6 level of obese individuals. In our study we found 
that there is significant correlation for Insulin resistance 
with serum IL-6.  
 Sum of Squares df Mean Square F Sig. 
Between Groups 102.375 2 51.187 44.991        .000 
Within Groups 53.473 47 1.138     
Total 155.848 49       
                     P Value=0.00 SIGNIFICANT 
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. Fernandez-real etal 33 study reported that among the 
cytokine which are secreted from adipose tissues IL-6 
play a key role in causing IR obese persons. Our study 
showed positive correlation body mass index and insulin 
resistance. In previous studies done by Garca- Estevez et 
al also had similar results34. In their study the increase in 
insulin resistance was noted when BMI increases above 
27.The p value for BMI and IR was  .26 which is a 
significant one. 
 Value Df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 7.303(a) 2 .026 
Likelihood Ratio 7.568 2 .023 
Linear-by-Linear Association 6.504 1 .011 
N of Valid Cases 50     
 P value =.026. 
Waist circumference and insulin resistance also showed a 
positive correlation in our study. In previous study by 
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Pouliot MC etal showed that waist circumference can be 
kept as best measure for abdominal visceral adipose 
tissue deposition35. Our study had a p value of .031 
which is significant.   
In our study we also found a significant correlation between 
W/H ratio and IR. It had a significant p value of .10 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 9.280(a) 2 .010 
Likelihood Ratio 8.893 2 .012 
Linear-by-Linear Association 7.916 1 .005 
N of Valid Cases 50     
    W/H ratio also had positive correlation with IL6 in our study 
it had a p value of .04. In obesity while considering insulin 
resistance both waist levels w/h ratio have a significant 
correlation 
While comparing TGL levels with IR and IL-6 we found a 
positive association for TGL levels with them.  
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Previous study by Qulec et al showed that serum TGL levels 
and BMI were positively correlated to IR. In our study also we 
found a similar result while comparing BMI, TGL levels with 
insulin resistance status in obese individuals.
36
. 
IR and TGL comparison had p value=.00 which is very 
significant.TGL and IL-6 had a P value =.00 which is very 
significant 
 TTGL N Mean Std. Deviation Std. Error Mean 
IIL6 < 150 19 2.974 .5772 .1324 
  >= 150 31 5.445 1.6114 .2894 
IR and TGL comparison had p value=.00 which is very 
significant.LDL had no positive association with IR as its p 
value was not significant. LDL also had no correlation with HT. 
Waist and weight had no positive correlation with HT as their p 
values were not significant.  
In our study we included 25 obese individuals who also had 
systemic hypertension and were on treatment. These patients 
had a positive correlation for insulin resistance. The P value for 
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comparison of hypertension and IR was .02 which is significant. 
In previous study regarding HT and IL-6 comparison by 
Bautista et al in 2005 showed a positive correlation.
37 
 HHT N Mean Std. Deviation 
Std. Error 
Mean 
IIL6 Yyes 25 5.216 1.8694 .3739 
  Nno 25 3.796 1.3960 .2792 
 P value =.04. 
The mean for IL-6 the patients who had hypertension was 5, 
while mean for non hypertensive obese was 3. The P value is 
.04. This inference of positive association of HT and IL-6 was 
similar to the previous study. 
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CONCLUSION 
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                              CONCLUSION 
1In obese non diabetic individuals evaluation of serum IL-6 may 
be heipful in assessment of insulin resistance. 
2.In obese hypertensives evaluation of serumIL-6 shows 
additive association for inflammatory cause. 
3 serum TGL levels are elevated in both obese hypertensives 
and obese with insulin resistance status Further studies are 
needed for confirmation. 
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PROFORMA 
SERUM INTERLEUKIN-6 LEVELS AND ITS CORRELATION WITH    
INSULIN  RESISTANCE  AND  SYTEMIC  HYPERTENSION  IN  OBESITY 
Name  :                                           Age  :                                           Sex  : 
Address :                                                                          
Occupation  
Symptoms : 
Polyuria 
Polydipsia 
Chest pain 
Palpitation 
Giddiness 
Breathlessness 
Past history: 
 
Diabetes mellitus: 
Duration: 
Treatment:  OHA/Insulin 
Compliance of treatment: 
Associated complications (if any) 
  
Hypertension -duration 
                          -treatment history 
 
Coronary artery disease 
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Other co morbid illnesses 
 
Thyroid disorders 
 
Personal history: 
 Smoking 
      Alcoholism 
 
General examination: 
Anthropometry: 
Height (in cm):         Weight(in kg):        Waist:         Hip: 
      
Waist/Hip ratio:                  Body mass index: 
 
PULSE: 
BLOOD PRESSURE: Right upper limb:        Left upper limb: 
 
          SYSTEMIC EXAMINATION: 
 
CARDIO VASCULAR SYSTEM: 
 
RESPIRATORY SYSTEM: 
 
ABDOMEN: 
94 
 
 
CENTRAL NERVOUS SYSTEM: 
 
FUNDUS EXAMINATION 
 
Complete Hemogram Renal function test 
TC  cells/mm
3
 Glucose (F)  mg/dl 
DC  Glucose (PP)  mg/dl 
ESR  mm/hr Urea  mg/dl 
Hb  g/dl Creatinine  mg/dl 
PCV  % Na+  mEq/l 
Platelets  lakhs/mm
3
 K+  mEq/l 
RBCs  million/mm
3
 Urinanalysis 
Lipid profile Albumin  
Total cholesterol  mg/dl Sugar  
LDL  mg/dl Deposits  
HDL  mg/dl Microalbumin  
Triglycerides  mg/dl Culture  
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LFT 
DB  mg/dl 
IB  mg/dl 
AST  IU 
ALT  IU 
ALP  IU 
TP  mg/dl 
ALB  mg/dl 
GLO  mg/dl 
 
X-ray chest 
Fasting blood sugar  
HbA1c 
Fasting Plasma Insulin  
 Serum Interleukin-6. 
Insulin resistance was calculated using HOMA-IR method. 
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MASTER CHART 
ID AGE Sex Height Wt BMI Waist Hip W/H LDL TGL HbA1c 
Fasting 
Insulin 
FBS HT IR IL6 
1 28 M 165 76 27.9 106 87 1.22 114 156 5.4 5.5 86 N 1.17 3.1 
2 32 M 150 70 31.1 96 80 1.2 130 176 4.9 9.6 90 N 2.13 4 
3 34 F 155 67 27.9 90 72 1.25 102 180 5 12 84 N 2.49 4.6 
4 30 M 162 78 29.7 82 96 0.85 98 114 4.3 4.5 80 N 0.89 2.6 
5 35 F 154 80 33.7 98 89 1.1 140 198 5.1 13.2 96 N 3.13 5.2 
6 28 M 172 96 32.4 95 109 0.87 112 134 5.4 5.1 84 N 1.06 2.8 
7 34 M 164 92 34.2 103 94 1.1 140 182 4.9 14.5 82 N 2.94 4.8 
8 26 M 159 83 32.8 93 102 0.91 124 132 5.4 4.9 90 N 1.09 3.4 
9 27 M 163 75 28.2 94 90 1.04 118 128 4.6 3.5 90 N 0.78 2.2 
10 30 F 157 79 32 96 83 1.16 134 158 4.2 7.6 84 N 1.58 3.8 
11 32 M 168 77 27.3 97 92 1.05 132 169 4.7 8.2 97 Y 1.96 4 
12 34 F 158 80 32 87 83 1.05 142 170 5.4 9.5 82 Y 1.92 4.3 
13 29 F 154 72 30.4 92 84 1.1 118 182 5.1 12.1 92 Y 2.75 6.4 
14 33 M 168 83 29.4 98 94 1.04 87 206 4.9 15.2 80 Y 3 7.3 
15 30 M 159 79 31.2 94 83 1.13 138 167 4.6 7.4 83 Y 1.52 4.4 
16 35 F 163 84 31.6 87 99 0.88 114 132 5.3 3.9 85 Y 0.82 2.5 
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ID AGE Sex Height Wt BMI Waist Hip W/H LDL TGL HbA1c 
Fasting 
Insulin 
FBS HT IR IL6 
17 28 M 172 102 34.5 108 94 1.15 156 195 5.5 19.2 94 Y 4.46 8.9 
18 34 M 165 86 31.6 96 87 1.1 94 112 4.7 5.5 80 Y 1.09 4.1 
19 29 F 157 70 28.4 89 86 1.03 132 153 5.2 8.8 78 Y 1.69 4.6 
20 31 M 162 78 29.7 97 92 1.05 98 161 4.7 7.9 80 Y 1.56 4.4 
21 29 F 154 69 29.1 87 92 0.95 87 94 5.3 4.8 92 Y 1.09 3.5 
22 35 M 166 84 30.5 97 83 1.17 137 188 4.8 18.2 77 Y 3.46 8.2 
23 33 F 158 74 29.6 88 85 1.04 117 137 4.5 5.3 89 Y 1.16 3.8 
24 31 F 153 69 29.5 87 85 1.02 88 169 5.6 6.7 98 Y 1.62 4.3 
25 27 M 169 82 28.7 94 92 1.02 102 113 5.1 4.7 79 N 0.92 2.9 
26 32 F 155 69 28.7 89 88 1.01 98 113 5.2 3.9 81 N 0.78 2.1 
27 34 M 164 78 29 101 92 1.1 114 122 4.7 4.2 85 N 0.88 2.4 
28 29 M 172 94 31.8 98 108 0.91 128 139 5.6 4.8 83 N 0.98 3 
29 34 M 168 97 34.4 102 92 1.11 138 167 5.1 12.2 96 N 2.89 5.1 
30 32 M 157 73 29.6 94 89 1.06 92 160 5.5 7.2 84 N 1.49 3.3 
31 27 M 162 88 33.5 109 98 1.11 147 168 5.6 16.5 90 N 3.67 6.2 
32 32 F 152 69 29.9 97 84 1.15 132 152 4.9 7.4 89 N 1.63 3.6 
33 27 F 149 64 28.8 92 104 0.88 128 147 5 3.9 85 N 0.82 2.4 
34 32 M 178 94 29.7 98 97 1.01 118 138 4.7 4.8 82 N 0.97 2.9 
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ID AGE Sex Height Wt BMI Waist Hip W/H LDL TGL HbA1c 
Fasting 
Insulin 
FBS HT IR IL6 
35 26 F 154 72 30.4 92 84 1.1 124 194 5.6 13.8 92 N 3.13 6.6 
36 29 F 163 72 27.1 89 106 0.84 138 174 4.8 12 82 N 2.43 5 
37 33 F 157 88 35.7 96 86 1.12 112 157 5.3 7.1 90 N 1.58 3.5 
38 31 M 169 90 31.5 98 94 1.04 96 132 4.6 3.8 87 N 0.82 2.5 
39 34 M 159 87 34.4 104 90 1.16 139 195 5.6 19.2 84 N 3.98 6.9 
40 35 M 160 72 28.1 89 98 0.91 94 122 4.6 3.9 81 Y 0.78 3.1 
41 32 F 155 82 34.1 106 95 1.12 168 172 5.5 13.7 89 Y 3.01 8 
42 28 F 157 73 29.6 89 84 1.06 158 179 4.3 12.3 88 Y 2.67 7.1 
43 34 M 164 77 28.6 93 100 0.93 86 93 5.4 4.3 78 Y 0.83 3.7 
44 32 M 172 90 30.4 102 93 1.1 110 158 4.9 15.9 82 Y 3.22 8.4 
45 30 F 161 80 30.9 92 89 1.03 146 128 4.6 4.2 80 Y 0.83 3.6 
46 28 F 156 68 27.9 84 82 1.02 98 155 5.3 8.9 82 Y 1.8 5.3 
47 33 M 169 85 29.8 94 103 0.91 110 123 5.6 3.4 87 Y 0.73 3 
48 29 M 159 74 29.3 98 93 1.05 147 162 4.9 7.8 94 Y 1.81 5.9 
49 32 F 157 72 29.2 93 87 1.07 134 159 5.3 8.9 87 Y 1.91 6.2 
50 28 M 160 79 30.9 99 95 1.04 129 153 5.6 8.5 81 Y 1.7 5.4 
 
